{"gene":"PNPO","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2005,"finding":"PNPO encodes pyridox(am)ine 5'-phosphate oxidase, the enzyme responsible for converting pyridoxamine 5'-phosphate and pyridoxine 5'-phosphate to pyridoxal 5'-phosphate (PLP). Splice site (IVS3-1g>a) and stop codon (X262Q) mutations in PNPO were null activity mutations, and the missense mutation R229W markedly reduced enzymatic activity, as demonstrated by expression studies in Chinese hamster ovary cells.","method":"Expression studies in CHO cells, enzymatic activity assays, PNPO gene sequencing","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic activity assay with mutagenesis, replicated across multiple patient mutations in a cell expression system","pmids":["15772097"],"is_preprint":false},{"year":1998,"finding":"PNPO cDNA encodes a functional pyridoxine-5'-phosphate oxidase; stable transfection of PNPO-negative hepatoma cell lines with the PNPO cDNA restored enzymatically active PNPO protein, confirming the cDNA encodes the rate-limiting enzyme in PLP biosynthesis. The translated product was immunologically reactive to a polyclonal PNPO antibody.","method":"Stable transfection of PNPO-negative hepatoma cell lines, enzymatic activity assay, immunological verification","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional reconstitution in cell lines plus immunological validation, single lab but two orthogonal methods","pmids":["9601034"],"is_preprint":false},{"year":2014,"finding":"Novel PNPO sequence changes, including R225H/C and D33V mutations, were shown to reduce enzyme activity using a cell-free expression system and a mass spectrometry-based assay for pyridoxamine phosphate oxidase. Many mutations affected residues involved in binding FMN (cofactor) or PLP (product), establishing structure-function relationships for these residues.","method":"Cell-free expression system, mass spectrometry-based enzymatic assay","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic assay with cell-free system and MS readout, single lab, multiple mutations tested","pmids":["24645144"],"is_preprint":false},{"year":2014,"finding":"The PNPO missense mutations p.Arg225His and p.Arg141Cys, and the deletion c.279_290del, were shown to reduce enzymatic activity by expression studies in CHO-K1 cell lines, establishing their pathogenicity. These mutations were absent in 100 control alleles.","method":"Expression studies in CHO-K1 cell lines, enzymatic activity assay","journal":"Neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic activity measurement in cell expression system, single lab, multiple mutations","pmids":["24658933"],"is_preprint":false},{"year":2008,"finding":"The novel PNPO mutation c.284G>A (p.Arg95His) in exon 3 reduces PNPO mutant enzymatic activity to 18% relative to wild type, as demonstrated by expression studies.","method":"Expression studies, enzymatic activity assay","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct quantitative enzymatic assay, single lab, single mutation","pmids":["18485777"],"is_preprint":false},{"year":2017,"finding":"The Arg116Gln PNPO variant, expressed as recombinant protein, does not alter overall enzyme structure but reduces affinity for the cofactor FMN, reduces thermal stability, slightly affects catalytic efficiency, and impairs transfer of PLP to PLP-dependent enzymes, establishing a mechanistic basis for partial loss of function.","method":"Recombinant protein expression, structural and kinetic characterization, FMN and PLP binding constants, thermal stability assay","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — recombinant protein with multiple orthogonal biochemical assays (kinetics, binding constants, thermal stability), single lab","pmids":["28818555","29379851"],"is_preprint":false},{"year":2019,"finding":"In Drosophila, silencing the PNPO ortholog sgll (sugarlethal) by RNAi causes chromosome aberrations in neuroblasts and induces diabetic hallmarks (hyperglycemia, small body size). Chromosome aberrations are largely caused by the genotoxic effect of advanced glycation end products triggered by high glucose, establishing that PNPO/PLP is required for both DNA integrity and glucose homeostasis.","method":"RNAi knockdown in Drosophila, chromosome aberration analysis, glucose measurement","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined cellular phenotypes and pathway placement, single lab, ortholog model","pmids":["31506944"],"is_preprint":false},{"year":2019,"finding":"CRISPR/Cas9-generated pnpo-/- zebrafish show reduction of PLP and pyridoxal with accumulation of PMP and pyridoxamine, confirming PNPO catalyzes the oxidation of PNP and PMP to PLP in vivo. Decreased GABA and glutamate result from impaired PLP-dependent enzyme activity. PLP treatment normalized PLP, glutamate, GABA, and glycine levels but did not normalize all amino acid profiles, suggesting additional roles for PMP accumulation in the disease phenotype.","method":"CRISPR/Cas9 knockout zebrafish, biochemical profiling (B6 vitamers, amino acids, neurotransmitters), PLP rescue","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with comprehensive biochemical profiling and rescue experiment, establishes in vivo catalytic function and downstream metabolic consequences","pmids":["31759955"],"is_preprint":false},{"year":2019,"finding":"Zebrafish pnpo knockdown (morpholino) causes brain malformation and impaired locomotor activity. These phenotypes are rescued by co-injection of zpnpo or hPNPO mRNA, or by PLP supplementation. Pyridoxamine (PM) supplementation showed rescue effects at lower concentrations than PLP, suggesting PM as an alternative substrate/therapeutic route. GABA supplementation also showed partial rescue, placing PNPO upstream of GABA synthesis.","method":"Morpholino knockdown in zebrafish, mRNA rescue, pharmacological supplementation, behavioral assay","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with mRNA rescue and multiple pharmacological interventions, single lab","pmids":["31616300"],"is_preprint":false},{"year":2022,"finding":"CRISPR-Cas9 knock-in Drosophila alleles carrying human PNPO epilepsy-associated variants (h116, h33, h95) exhibit allele-dependent phenotypes (developmental impairments, seizures, shortened lifespan) correlating with the known biochemical severity of each mutation. The hR95H allele has a dominant-negative effect, rendering heterozygous flies susceptible to seizures and premature death. PLP supplementation prevented developmental impairments and seizures.","method":"CRISPR-Cas9 knock-in Drosophila, behavioral analysis, PLP dietary supplementation rescue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple alleles with allele-dependent phenotypes, dominant-negative characterization, rescue experiments, systematic genotype-phenotype correlation","pmids":["35217610"],"is_preprint":false},{"year":2024,"finding":"PNPO acts as an oxygen sensor in macrophages: decreased PNPO activity under prolonged hypoxia reduces PLP levels, inhibiting lysosomal acidification. This leads to iron dysregulation, TET2 protein loss, and delayed resolution of inflammatory response. Among PLP-dependent metabolic pathways, supersulfide synthesis is specifically suppressed under prolonged hypoxia, mechanistically linking PNPO activity to lysosomal function and macrophage inflammatory phenotype.","method":"Macrophage hypoxia model, PNPO activity assay, lysosomal acidification assay, iron and TET2 protein measurement, supersulfide metabolite profiling","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays (lysosomal acidification, TET2 protein, iron, metabolomics) in a defined cellular context, mechanistic pathway established, single lab","pmids":["38822028"],"is_preprint":false},{"year":2024,"finding":"PNPO oxidizes disheveled 3 at Met282 (DVL3M282), leading to abnormal activation of the Wnt/β-catenin pathway in multiple myeloma cells. Critical PNPO residues R95 and K117 are required for interaction with DVL3. Disrupting the PNPO-DVL3 interaction (with Eltrombopag) inhibited MM cell growth and reduced bone lesions in mouse models.","method":"Celastrol probe target identification, co-IP/interaction studies, mutagenesis of PNPO (R95, K117), Wnt/β-catenin pathway reporter, mouse xenograft model, DVL3 oxidation assay","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction and oxidation mechanism with mutagenesis and in vivo validation, single lab","pmids":["39656865"],"is_preprint":false},{"year":2024,"finding":"PNPO promotes lysosomal biogenesis and perinuclear distribution, enhancing autophagic flux in ovarian cancer cells via a PNPO-LAMP2 axis. LAMP2 silencing blocked PNPO's effect on cellular processes. PNPO also regulates cell cycle progression via cyclin B1 and phosphorylated CDK1.","method":"siRNA knockdown, overexpression, LAMP2 co-silencing, cell cycle analysis, xenograft tumor model","journal":"Apoptosis : an international journal on programmed cell death","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis experiment (LAMP2 siRNA blocks PNPO effect) placing PNPO upstream of LAMP2 in lysosomal regulation, single lab with multiple readouts","pmids":["38615082"],"is_preprint":false},{"year":2025,"finding":"In Drosophila sgll (PNPO ortholog) mutants, cell-autonomous expression of human PNPO cDNA specifically in GABAergic neurons largely restored lifespan and attenuated seizure activity, while expression in cholinergic or glutamatergic neurons did not. Glial expression provided partial rescue. GABA-B agonist SKF-97541 (but not GABA-A modulators) reduced mortality, establishing that PNPO acts cell-autonomously in GABAergic neurons to support brain function.","method":"Cell-type-specific hPNPO cDNA rescue in Drosophila sgll mutants, survival and seizure behavioral assays, pharmacological GABA receptor modulation","journal":"Journal of neurogenetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic rescue with multiple cell types tested, combined with pharmacological epistasis, establishes cell-autonomous pathway placement","pmids":["41296493"],"is_preprint":false},{"year":2025,"finding":"In Drosophila PNPO (sgll) mutants, PNPO deficiency reduces alcohol aversion, increases alcohol consumption, and alters locomotor behavior. Biochemically, both PNPO deficiency and alcohol exposure elevate GABA and glycine. VB6 supplementation rescues lethality caused by combined PNPO deficiency and alcohol, establishing a functional interaction between genetic VB6 deficiency and alcohol at the level of inhibitory neurotransmitter metabolism.","method":"Drosophila PNPO mutant model, behavioral assays (alcohol aversion, consumption, locomotion), amino acid/neurotransmitter metabolomics, VB6 supplementation rescue","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic model with behavioral and biochemical readouts, preprint not yet peer-reviewed, single lab","pmids":["bio_10.1101_2025.03.06.641947"],"is_preprint":true}],"current_model":"PNPO (pyridox(am)ine 5'-phosphate oxidase) is the rate-limiting enzyme that catalyzes oxidation of pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) to pyridoxal 5'-phosphate (PLP), the active form of vitamin B6 required as cofactor for >100 enzymes including those synthesizing GABA and monoamine neurotransmitters; it requires FMN as cofactor, functions as a dimer, and loss-of-function mutations cause neonatal epileptic encephalopathy by depleting PLP; beyond vitamin B6 metabolism, PNPO acts as an oxygen sensor in macrophages linking prolonged hypoxia to lysosomal inhibition and inflammation via supersulfide synthesis, directly oxidizes DVL3 to activate Wnt/β-catenin signaling in myeloma, promotes autophagic flux through a PNPO-LAMP2 axis in cancer cells, and is required cell-autonomously in GABAergic neurons for seizure suppression."},"narrative":{"mechanistic_narrative":"PNPO encodes pyridox(am)ine 5'-phosphate oxidase, the rate-limiting FMN-dependent enzyme that oxidizes pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) to pyridoxal 5'-phosphate (PLP), the active vitamin B6 cofactor [PMID:9601034, PMID:31759955]. Loss-of-function mutations — including null splice-site and stop-codon alleles and activity-reducing missense changes — cause neonatal epileptic encephalopathy, with pathogenicity established by reduced enzymatic activity in cell expression and recombinant systems; many disease residues map to FMN-cofactor or PLP-product binding sites, and partial-function variants act by lowering FMN affinity, destabilizing the protein, and impairing transfer of PLP to downstream apoenzymes [PMID:15772097, PMID:24645144, PMID:28818555, PMID:29379851]. In vivo, PNPO loss depletes PLP and pyridoxal while PMP and pyridoxamine accumulate, lowering PLP-dependent synthesis of GABA, glutamate, and glycine; PLP supplementation rescues neurotransmitter levels and behavioral and seizure phenotypes, placing PNPO upstream of inhibitory neurotransmitter metabolism [PMID:31759955, PMID:31616300, PMID:35217610]. PNPO functions cell-autonomously in GABAergic neurons to support survival and suppress seizures [PMID:41296493]. Beyond canonical B6 metabolism, PNPO activity serves as an oxygen sensor in macrophages, where hypoxic loss of PLP impairs lysosomal acidification and supersulfide synthesis and delays inflammatory resolution [PMID:38822028]; PNPO oxidizes Disheveled-3 at Met282 to activate Wnt/β-catenin signaling in myeloma via residues R95 and K117 [PMID:39656865]; and it promotes autophagic flux and lysosomal biogenesis through a PNPO–LAMP2 axis in cancer cells [PMID:38615082].","teleology":[{"year":1998,"claim":"Established that the PNPO cDNA encodes a functional, rate-limiting enzyme of PLP biosynthesis, defining the gene's core catalytic identity.","evidence":"stable transfection of PNPO-negative hepatoma cell lines with enzymatic and immunological readout","pmids":["9601034"],"confidence":"High","gaps":["No structural model of the enzyme","Cofactor and oligomeric requirements not defined here"]},{"year":2005,"claim":"Linked PNPO loss-of-function to human disease by showing patient mutations abolish or markedly reduce catalytic activity, establishing causality for a vitamin B6-responsive encephalopathy.","evidence":"expression of patient splice, nonsense, and missense alleles in CHO cells with activity assays","pmids":["15772097"],"confidence":"High","gaps":["Mechanism connecting PLP depletion to seizures not yet shown","No in vivo model"]},{"year":2008,"claim":"Extended the genotype-activity map with an additional missense allele retaining residual activity, refining understanding of partial loss-of-function.","evidence":"expression studies and quantitative enzyme assay of p.Arg95His","pmids":["18485777"],"confidence":"Medium","gaps":["Single mutation","No structural rationale provided"]},{"year":2014,"claim":"Mapped pathogenic residues onto FMN-cofactor and PLP-product binding sites, building a structure-function basis for how mutations impair catalysis.","evidence":"cell-free expression with mass-spectrometry activity assay and CHO-K1 expression across multiple mutations","pmids":["24645144","24658933"],"confidence":"Medium","gaps":["No high-resolution structure of mutant enzymes","Binding affinities not directly measured"]},{"year":2017,"claim":"Defined a precise biochemical mechanism for partial loss of function, showing a variant reduces FMN affinity and thermal stability and impairs PLP delivery to apoenzymes without globally unfolding the protein.","evidence":"recombinant protein kinetics, FMN/PLP binding constants, and thermal stability assays","pmids":["28818555","29379851"],"confidence":"High","gaps":["Single variant characterized in depth","Mechanism of PLP channeling to apoenzymes not resolved"]},{"year":2019,"claim":"Demonstrated in vivo that PNPO loss shifts the B6 vitamer balance and depletes GABA and glutamate, with PLP rescue, directly tying enzyme deficiency to neurotransmitter metabolism and brain phenotypes.","evidence":"CRISPR/Cas9 knockout and morpholino knockdown zebrafish with vitamer/neurotransmitter profiling, mRNA and PLP/pyridoxamine rescue; plus Drosophila sgll RNAi with chromosome and glucose phenotypes","pmids":["31759955","31616300","31506944"],"confidence":"High","gaps":["Residual phenotypes after PLP rescue point to unexplained PMP-related effects","Drosophila DNA-integrity/glucose link not validated in mammals"]},{"year":2022,"claim":"Established allele-dependent genotype-phenotype correlation and a dominant-negative mechanism in vivo, showing biochemical severity predicts organismal seizure and survival outcomes.","evidence":"CRISPR knock-in Drosophila carrying human epilepsy variants with behavioral assays and PLP dietary rescue","pmids":["35217610"],"confidence":"High","gaps":["Molecular basis of dominant-negative effect (e.g., dimer poisoning) not directly demonstrated","Mammalian confirmation lacking"]},{"year":2024,"claim":"Revealed non-canonical roles: PNPO activity senses oxygen to control lysosomal acidification and inflammation, directly oxidizes DVL3 to drive Wnt signaling, and supports autophagy via a LAMP2 axis, expanding PNPO beyond a metabolic housekeeping enzyme.","evidence":"macrophage hypoxia model with lysosomal/TET2/iron/supersulfide readouts; celastrol-probe target ID, co-IP, PNPO R95/K117 mutagenesis, DVL3 oxidation and xenografts; siRNA/overexpression with LAMP2 epistasis and cell-cycle analysis","pmids":["38822028","39656865","38615082"],"confidence":"Medium","gaps":["Each non-canonical role characterized in a single context/lab","How a B6 oxidase oxidizes a protein methionine substrate mechanistically unresolved","Relationship between metabolic and signaling functions unclear"]},{"year":2025,"claim":"Localized PNPO's neurological function to GABAergic neurons cell-autonomously and showed a functional interaction with alcohol at the level of inhibitory neurotransmitter metabolism.","evidence":"cell-type-specific hPNPO rescue in Drosophila sgll mutants with GABA-receptor pharmacology; PNPO-deficient flies with alcohol behavioral assays and VB6 rescue (the alcohol study is a preprint)","pmids":["41296493","bio_10.1101_2025.03.06.641947"],"confidence":"High","gaps":["Partial glial rescue not mechanistically explained","Mammalian cell-type-specific requirement not tested","Alcohol interaction is preprint-stage"]},{"year":null,"claim":"How PNPO's metabolic (PLP-generating) and non-canonical (protein-oxidizing, oxygen-sensing, lysosome-regulating) activities are integrated within a single enzyme remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of PNPO bound to non-canonical substrates such as DVL3","Unclear whether signaling functions depend on PLP output or are catalytically independent","Mammalian validation of expanded roles pending"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,7,11]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[5,7]}],"localization":[],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,7]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[8,13]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11]}],"complexes":[],"partners":["DVL3","LAMP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NVS9","full_name":"Pyridoxine-5'-phosphate oxidase","aliases":["Pyridoxamine-phosphate oxidase"],"length_aa":261,"mass_kda":30.0,"function":"Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q9NVS9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PNPO","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PNPO","total_profiled":1310},"omim":[{"mim_id":"610090","title":"PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD","url":"https://www.omim.org/entry/610090"},{"mim_id":"603287","title":"PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE; PNPO","url":"https://www.omim.org/entry/603287"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":82.9}],"url":"https://www.proteinatlas.org/search/PNPO"},"hgnc":{"alias_symbol":["PDXPO"],"prev_symbol":[]},"alphafold":{"accession":"Q9NVS9","domains":[{"cath_id":"2.30.110.10","chopping":"45-161_204-257","consensus_level":"high","plddt":95.646,"start":45,"end":257}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVS9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVS9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVS9-F1-predicted_aligned_error_v6.png","plddt_mean":88.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PNPO","jax_strain_url":"https://www.jax.org/strain/search?query=PNPO"},"sequence":{"accession":"Q9NVS9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NVS9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NVS9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVS9"}},"corpus_meta":[{"pmid":"15772097","id":"PMC_15772097","title":"Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15772097","citation_count":219,"is_preprint":false},{"pmid":"24645144","id":"PMC_24645144","title":"Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24645144","citation_count":144,"is_preprint":false},{"pmid":"24658933","id":"PMC_24658933","title":"Pyridoxine responsiveness in novel mutations of the PNPO gene.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24658933","citation_count":75,"is_preprint":false},{"pmid":"18024216","id":"PMC_18024216","title":"A new fatal case of pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.","date":"2007","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18024216","citation_count":48,"is_preprint":false},{"pmid":"18485777","id":"PMC_18485777","title":"PNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism.","date":"2008","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18485777","citation_count":43,"is_preprint":false},{"pmid":"23430561","id":"PMC_23430561","title":"Partial Pyridoxine Responsiveness in PNPO Deficiency.","date":"2012","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/23430561","citation_count":36,"is_preprint":false},{"pmid":"9601034","id":"PMC_9601034","title":"Absence of pyridoxine-5'-phosphate oxidase (PNPO) activity in neoplastic cells: isolation, characterization, and expression of PNPO cDNA.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9601034","citation_count":31,"is_preprint":false},{"pmid":"28818555","id":"PMC_28818555","title":"Pyridoxine-5'-phosphate oxidase (Pnpo) deficiency: Clinical and biochemical alterations associated with the C.347g>A (P.·Arg116gln) mutation.","date":"2017","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28818555","citation_count":29,"is_preprint":false},{"pmid":"27014579","id":"PMC_27014579","title":"Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation.","date":"2016","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/27014579","citation_count":28,"is_preprint":false},{"pmid":"31506944","id":"PMC_31506944","title":"Pyridoxine/pyridoxamine 5'-phosphate oxidase (Sgll/PNPO) is important for DNA integrity and glucose homeostasis maintenance in Drosophila.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31506944","citation_count":24,"is_preprint":false},{"pmid":"31759955","id":"PMC_31759955","title":"Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency in zebrafish results in fatal seizures and metabolic aberrations.","date":"2019","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31759955","citation_count":22,"is_preprint":false},{"pmid":"26108646","id":"PMC_26108646","title":"PNPO Deficiency and Cirrhosis: Expanding the Clinical Phenotype?","date":"2015","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/26108646","citation_count":21,"is_preprint":false},{"pmid":"25762494","id":"PMC_25762494","title":"Normal Cerebrospinal Fluid Pyridoxal 5'-Phosphate Level in a PNPO-Deficient Patient with Neonatal-Onset Epileptic Encephalopathy.","date":"2015","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/25762494","citation_count":18,"is_preprint":false},{"pmid":"38822028","id":"PMC_38822028","title":"PNPO-PLP axis senses prolonged hypoxia in macrophages by regulating lysosomal activity.","date":"2024","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38822028","citation_count":15,"is_preprint":false},{"pmid":"35217610","id":"PMC_35217610","title":"Drosophila carrying epilepsy-associated variants in the vitamin B6 metabolism gene PNPO display allele- and diet-dependent phenotypes.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35217610","citation_count":15,"is_preprint":false},{"pmid":"26535729","id":"PMC_26535729","title":"Pyridoxal 5ꞌ-phosphate-responsive epilepsy with novel mutations in the PNPO gene: a case report.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26535729","citation_count":13,"is_preprint":false},{"pmid":"39656865","id":"PMC_39656865","title":"PNPO-Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-Catenin Pathway.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39656865","citation_count":11,"is_preprint":false},{"pmid":"29379851","id":"PMC_29379851","title":"Biochemical data from the characterization of a new pathogenic mutation of human pyridoxine-5'-phosphate oxidase (PNPO).","date":"2017","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/29379851","citation_count":11,"is_preprint":false},{"pmid":"32395712","id":"PMC_32395712","title":"Variable treatment response in a patient with pyridoxal N phosphate oxidase (PNPO) deficiency- understanding the paradox.","date":"2020","source":"Epilepsy & behavior reports","url":"https://pubmed.ncbi.nlm.nih.gov/32395712","citation_count":8,"is_preprint":false},{"pmid":"17851041","id":"PMC_17851041","title":"Association between PNPO and schizophrenia in the Japanese population.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/17851041","citation_count":7,"is_preprint":false},{"pmid":"31616300","id":"PMC_31616300","title":"Pyridoxamine Supplementation Effectively Reverses the Abnormal Phenotypes of Zebrafish Larvae With PNPO Deficiency.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31616300","citation_count":7,"is_preprint":false},{"pmid":"38615082","id":"PMC_38615082","title":"Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.","date":"2024","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/38615082","citation_count":6,"is_preprint":false},{"pmid":"41296493","id":"PMC_41296493","title":"A cell-autonomous role for the vitamin B6 metabolism gene PNPO in Drosophila GABAergic neurons.","date":"2025","source":"Journal of neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/41296493","citation_count":0,"is_preprint":false},{"pmid":"41914238","id":"PMC_41914238","title":"Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol-Inspired Approach.","date":"2026","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/41914238","citation_count":0,"is_preprint":false},{"pmid":"42016347","id":"PMC_42016347","title":"Should PNPO Deficiency Be Treated In Utero? Clinical Findings From Prenatal Pyridoxine Therapy.","date":"2026","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/42016347","citation_count":0,"is_preprint":false},{"pmid":"42027653","id":"PMC_42027653","title":"Integration of Multi-Omics Data Identifies the Role of the Selenium-Related Gene PNPO and Pre-exhausted CD127- CD8+ T Cells in Laryngeal Carcinoma.","date":"2026","source":"Cancer informatics","url":"https://pubmed.ncbi.nlm.nih.gov/42027653","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.07.669010","title":"A Cell-Autonomous Role for the Vitamin B6 Metabolism Gene  <i>PNPO</i>  in  <i>Drosophila</i>  GABAergic Neurons","date":"2025-08-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.07.669010","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.20.25338428","title":"Sex-Specific Cord Blood DNA Methylation Signatures for Childhood ADHD Symptoms","date":"2025-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.20.25338428","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.06.641947","title":"Genetic vitamin B6 deficiency and alcohol interaction in behavior and metabolism","date":"2025-03-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.06.641947","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15918,"output_tokens":3919,"usd":0.053269,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11915,"output_tokens":3307,"usd":0.071125,"stage2_stop_reason":"end_turn"},"total_usd":0.124394,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"PNPO encodes pyridox(am)ine 5'-phosphate oxidase, the enzyme responsible for converting pyridoxamine 5'-phosphate and pyridoxine 5'-phosphate to pyridoxal 5'-phosphate (PLP). Splice site (IVS3-1g>a) and stop codon (X262Q) mutations in PNPO were null activity mutations, and the missense mutation R229W markedly reduced enzymatic activity, as demonstrated by expression studies in Chinese hamster ovary cells.\",\n      \"method\": \"Expression studies in CHO cells, enzymatic activity assays, PNPO gene sequencing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic activity assay with mutagenesis, replicated across multiple patient mutations in a cell expression system\",\n      \"pmids\": [\"15772097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PNPO cDNA encodes a functional pyridoxine-5'-phosphate oxidase; stable transfection of PNPO-negative hepatoma cell lines with the PNPO cDNA restored enzymatically active PNPO protein, confirming the cDNA encodes the rate-limiting enzyme in PLP biosynthesis. The translated product was immunologically reactive to a polyclonal PNPO antibody.\",\n      \"method\": \"Stable transfection of PNPO-negative hepatoma cell lines, enzymatic activity assay, immunological verification\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional reconstitution in cell lines plus immunological validation, single lab but two orthogonal methods\",\n      \"pmids\": [\"9601034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Novel PNPO sequence changes, including R225H/C and D33V mutations, were shown to reduce enzyme activity using a cell-free expression system and a mass spectrometry-based assay for pyridoxamine phosphate oxidase. Many mutations affected residues involved in binding FMN (cofactor) or PLP (product), establishing structure-function relationships for these residues.\",\n      \"method\": \"Cell-free expression system, mass spectrometry-based enzymatic assay\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic assay with cell-free system and MS readout, single lab, multiple mutations tested\",\n      \"pmids\": [\"24645144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The PNPO missense mutations p.Arg225His and p.Arg141Cys, and the deletion c.279_290del, were shown to reduce enzymatic activity by expression studies in CHO-K1 cell lines, establishing their pathogenicity. These mutations were absent in 100 control alleles.\",\n      \"method\": \"Expression studies in CHO-K1 cell lines, enzymatic activity assay\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic activity measurement in cell expression system, single lab, multiple mutations\",\n      \"pmids\": [\"24658933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The novel PNPO mutation c.284G>A (p.Arg95His) in exon 3 reduces PNPO mutant enzymatic activity to 18% relative to wild type, as demonstrated by expression studies.\",\n      \"method\": \"Expression studies, enzymatic activity assay\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct quantitative enzymatic assay, single lab, single mutation\",\n      \"pmids\": [\"18485777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The Arg116Gln PNPO variant, expressed as recombinant protein, does not alter overall enzyme structure but reduces affinity for the cofactor FMN, reduces thermal stability, slightly affects catalytic efficiency, and impairs transfer of PLP to PLP-dependent enzymes, establishing a mechanistic basis for partial loss of function.\",\n      \"method\": \"Recombinant protein expression, structural and kinetic characterization, FMN and PLP binding constants, thermal stability assay\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — recombinant protein with multiple orthogonal biochemical assays (kinetics, binding constants, thermal stability), single lab\",\n      \"pmids\": [\"28818555\", \"29379851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In Drosophila, silencing the PNPO ortholog sgll (sugarlethal) by RNAi causes chromosome aberrations in neuroblasts and induces diabetic hallmarks (hyperglycemia, small body size). Chromosome aberrations are largely caused by the genotoxic effect of advanced glycation end products triggered by high glucose, establishing that PNPO/PLP is required for both DNA integrity and glucose homeostasis.\",\n      \"method\": \"RNAi knockdown in Drosophila, chromosome aberration analysis, glucose measurement\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined cellular phenotypes and pathway placement, single lab, ortholog model\",\n      \"pmids\": [\"31506944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRISPR/Cas9-generated pnpo-/- zebrafish show reduction of PLP and pyridoxal with accumulation of PMP and pyridoxamine, confirming PNPO catalyzes the oxidation of PNP and PMP to PLP in vivo. Decreased GABA and glutamate result from impaired PLP-dependent enzyme activity. PLP treatment normalized PLP, glutamate, GABA, and glycine levels but did not normalize all amino acid profiles, suggesting additional roles for PMP accumulation in the disease phenotype.\",\n      \"method\": \"CRISPR/Cas9 knockout zebrafish, biochemical profiling (B6 vitamers, amino acids, neurotransmitters), PLP rescue\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with comprehensive biochemical profiling and rescue experiment, establishes in vivo catalytic function and downstream metabolic consequences\",\n      \"pmids\": [\"31759955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Zebrafish pnpo knockdown (morpholino) causes brain malformation and impaired locomotor activity. These phenotypes are rescued by co-injection of zpnpo or hPNPO mRNA, or by PLP supplementation. Pyridoxamine (PM) supplementation showed rescue effects at lower concentrations than PLP, suggesting PM as an alternative substrate/therapeutic route. GABA supplementation also showed partial rescue, placing PNPO upstream of GABA synthesis.\",\n      \"method\": \"Morpholino knockdown in zebrafish, mRNA rescue, pharmacological supplementation, behavioral assay\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with mRNA rescue and multiple pharmacological interventions, single lab\",\n      \"pmids\": [\"31616300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRISPR-Cas9 knock-in Drosophila alleles carrying human PNPO epilepsy-associated variants (h116, h33, h95) exhibit allele-dependent phenotypes (developmental impairments, seizures, shortened lifespan) correlating with the known biochemical severity of each mutation. The hR95H allele has a dominant-negative effect, rendering heterozygous flies susceptible to seizures and premature death. PLP supplementation prevented developmental impairments and seizures.\",\n      \"method\": \"CRISPR-Cas9 knock-in Drosophila, behavioral analysis, PLP dietary supplementation rescue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple alleles with allele-dependent phenotypes, dominant-negative characterization, rescue experiments, systematic genotype-phenotype correlation\",\n      \"pmids\": [\"35217610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PNPO acts as an oxygen sensor in macrophages: decreased PNPO activity under prolonged hypoxia reduces PLP levels, inhibiting lysosomal acidification. This leads to iron dysregulation, TET2 protein loss, and delayed resolution of inflammatory response. Among PLP-dependent metabolic pathways, supersulfide synthesis is specifically suppressed under prolonged hypoxia, mechanistically linking PNPO activity to lysosomal function and macrophage inflammatory phenotype.\",\n      \"method\": \"Macrophage hypoxia model, PNPO activity assay, lysosomal acidification assay, iron and TET2 protein measurement, supersulfide metabolite profiling\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays (lysosomal acidification, TET2 protein, iron, metabolomics) in a defined cellular context, mechanistic pathway established, single lab\",\n      \"pmids\": [\"38822028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PNPO oxidizes disheveled 3 at Met282 (DVL3M282), leading to abnormal activation of the Wnt/β-catenin pathway in multiple myeloma cells. Critical PNPO residues R95 and K117 are required for interaction with DVL3. Disrupting the PNPO-DVL3 interaction (with Eltrombopag) inhibited MM cell growth and reduced bone lesions in mouse models.\",\n      \"method\": \"Celastrol probe target identification, co-IP/interaction studies, mutagenesis of PNPO (R95, K117), Wnt/β-catenin pathway reporter, mouse xenograft model, DVL3 oxidation assay\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction and oxidation mechanism with mutagenesis and in vivo validation, single lab\",\n      \"pmids\": [\"39656865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PNPO promotes lysosomal biogenesis and perinuclear distribution, enhancing autophagic flux in ovarian cancer cells via a PNPO-LAMP2 axis. LAMP2 silencing blocked PNPO's effect on cellular processes. PNPO also regulates cell cycle progression via cyclin B1 and phosphorylated CDK1.\",\n      \"method\": \"siRNA knockdown, overexpression, LAMP2 co-silencing, cell cycle analysis, xenograft tumor model\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis experiment (LAMP2 siRNA blocks PNPO effect) placing PNPO upstream of LAMP2 in lysosomal regulation, single lab with multiple readouts\",\n      \"pmids\": [\"38615082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Drosophila sgll (PNPO ortholog) mutants, cell-autonomous expression of human PNPO cDNA specifically in GABAergic neurons largely restored lifespan and attenuated seizure activity, while expression in cholinergic or glutamatergic neurons did not. Glial expression provided partial rescue. GABA-B agonist SKF-97541 (but not GABA-A modulators) reduced mortality, establishing that PNPO acts cell-autonomously in GABAergic neurons to support brain function.\",\n      \"method\": \"Cell-type-specific hPNPO cDNA rescue in Drosophila sgll mutants, survival and seizure behavioral assays, pharmacological GABA receptor modulation\",\n      \"journal\": \"Journal of neurogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic rescue with multiple cell types tested, combined with pharmacological epistasis, establishes cell-autonomous pathway placement\",\n      \"pmids\": [\"41296493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Drosophila PNPO (sgll) mutants, PNPO deficiency reduces alcohol aversion, increases alcohol consumption, and alters locomotor behavior. Biochemically, both PNPO deficiency and alcohol exposure elevate GABA and glycine. VB6 supplementation rescues lethality caused by combined PNPO deficiency and alcohol, establishing a functional interaction between genetic VB6 deficiency and alcohol at the level of inhibitory neurotransmitter metabolism.\",\n      \"method\": \"Drosophila PNPO mutant model, behavioral assays (alcohol aversion, consumption, locomotion), amino acid/neurotransmitter metabolomics, VB6 supplementation rescue\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic model with behavioral and biochemical readouts, preprint not yet peer-reviewed, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.03.06.641947\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PNPO (pyridox(am)ine 5'-phosphate oxidase) is the rate-limiting enzyme that catalyzes oxidation of pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) to pyridoxal 5'-phosphate (PLP), the active form of vitamin B6 required as cofactor for >100 enzymes including those synthesizing GABA and monoamine neurotransmitters; it requires FMN as cofactor, functions as a dimer, and loss-of-function mutations cause neonatal epileptic encephalopathy by depleting PLP; beyond vitamin B6 metabolism, PNPO acts as an oxygen sensor in macrophages linking prolonged hypoxia to lysosomal inhibition and inflammation via supersulfide synthesis, directly oxidizes DVL3 to activate Wnt/β-catenin signaling in myeloma, promotes autophagic flux through a PNPO-LAMP2 axis in cancer cells, and is required cell-autonomously in GABAergic neurons for seizure suppression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PNPO encodes pyridox(am)ine 5'-phosphate oxidase, the rate-limiting FMN-dependent enzyme that oxidizes pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) to pyridoxal 5'-phosphate (PLP), the active vitamin B6 cofactor [#1, #7]. Loss-of-function mutations — including null splice-site and stop-codon alleles and activity-reducing missense changes — cause neonatal epileptic encephalopathy, with pathogenicity established by reduced enzymatic activity in cell expression and recombinant systems; many disease residues map to FMN-cofactor or PLP-product binding sites, and partial-function variants act by lowering FMN affinity, destabilizing the protein, and impairing transfer of PLP to downstream apoenzymes [#0, #2, #5]. In vivo, PNPO loss depletes PLP and pyridoxal while PMP and pyridoxamine accumulate, lowering PLP-dependent synthesis of GABA, glutamate, and glycine; PLP supplementation rescues neurotransmitter levels and behavioral and seizure phenotypes, placing PNPO upstream of inhibitory neurotransmitter metabolism [#7, #8, #9]. PNPO functions cell-autonomously in GABAergic neurons to support survival and suppress seizures [#13]. Beyond canonical B6 metabolism, PNPO activity serves as an oxygen sensor in macrophages, where hypoxic loss of PLP impairs lysosomal acidification and supersulfide synthesis and delays inflammatory resolution [#10]; PNPO oxidizes Disheveled-3 at Met282 to activate Wnt/\\u03b2-catenin signaling in myeloma via residues R95 and K117 [#11]; and it promotes autophagic flux and lysosomal biogenesis through a PNPO\\u2013LAMP2 axis in cancer cells [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that the PNPO cDNA encodes a functional, rate-limiting enzyme of PLP biosynthesis, defining the gene's core catalytic identity.\",\n      \"evidence\": \"stable transfection of PNPO-negative hepatoma cell lines with enzymatic and immunological readout\",\n      \"pmids\": [\"9601034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of the enzyme\", \"Cofactor and oligomeric requirements not defined here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked PNPO loss-of-function to human disease by showing patient mutations abolish or markedly reduce catalytic activity, establishing causality for a vitamin B6-responsive encephalopathy.\",\n      \"evidence\": \"expression of patient splice, nonsense, and missense alleles in CHO cells with activity assays\",\n      \"pmids\": [\"15772097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting PLP depletion to seizures not yet shown\", \"No in vivo model\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended the genotype-activity map with an additional missense allele retaining residual activity, refining understanding of partial loss-of-function.\",\n      \"evidence\": \"expression studies and quantitative enzyme assay of p.Arg95His\",\n      \"pmids\": [\"18485777\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single mutation\", \"No structural rationale provided\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped pathogenic residues onto FMN-cofactor and PLP-product binding sites, building a structure-function basis for how mutations impair catalysis.\",\n      \"evidence\": \"cell-free expression with mass-spectrometry activity assay and CHO-K1 expression across multiple mutations\",\n      \"pmids\": [\"24645144\", \"24658933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of mutant enzymes\", \"Binding affinities not directly measured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a precise biochemical mechanism for partial loss of function, showing a variant reduces FMN affinity and thermal stability and impairs PLP delivery to apoenzymes without globally unfolding the protein.\",\n      \"evidence\": \"recombinant protein kinetics, FMN/PLP binding constants, and thermal stability assays\",\n      \"pmids\": [\"28818555\", \"29379851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single variant characterized in depth\", \"Mechanism of PLP channeling to apoenzymes not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated in vivo that PNPO loss shifts the B6 vitamer balance and depletes GABA and glutamate, with PLP rescue, directly tying enzyme deficiency to neurotransmitter metabolism and brain phenotypes.\",\n      \"evidence\": \"CRISPR/Cas9 knockout and morpholino knockdown zebrafish with vitamer/neurotransmitter profiling, mRNA and PLP/pyridoxamine rescue; plus Drosophila sgll RNAi with chromosome and glucose phenotypes\",\n      \"pmids\": [\"31759955\", \"31616300\", \"31506944\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Residual phenotypes after PLP rescue point to unexplained PMP-related effects\", \"Drosophila DNA-integrity/glucose link not validated in mammals\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established allele-dependent genotype-phenotype correlation and a dominant-negative mechanism in vivo, showing biochemical severity predicts organismal seizure and survival outcomes.\",\n      \"evidence\": \"CRISPR knock-in Drosophila carrying human epilepsy variants with behavioral assays and PLP dietary rescue\",\n      \"pmids\": [\"35217610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of dominant-negative effect (e.g., dimer poisoning) not directly demonstrated\", \"Mammalian confirmation lacking\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed non-canonical roles: PNPO activity senses oxygen to control lysosomal acidification and inflammation, directly oxidizes DVL3 to drive Wnt signaling, and supports autophagy via a LAMP2 axis, expanding PNPO beyond a metabolic housekeeping enzyme.\",\n      \"evidence\": \"macrophage hypoxia model with lysosomal/TET2/iron/supersulfide readouts; celastrol-probe target ID, co-IP, PNPO R95/K117 mutagenesis, DVL3 oxidation and xenografts; siRNA/overexpression with LAMP2 epistasis and cell-cycle analysis\",\n      \"pmids\": [\"38822028\", \"39656865\", \"38615082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each non-canonical role characterized in a single context/lab\", \"How a B6 oxidase oxidizes a protein methionine substrate mechanistically unresolved\", \"Relationship between metabolic and signaling functions unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Localized PNPO's neurological function to GABAergic neurons cell-autonomously and showed a functional interaction with alcohol at the level of inhibitory neurotransmitter metabolism.\",\n      \"evidence\": \"cell-type-specific hPNPO rescue in Drosophila sgll mutants with GABA-receptor pharmacology; PNPO-deficient flies with alcohol behavioral assays and VB6 rescue (the alcohol study is a preprint)\",\n      \"pmids\": [\"41296493\", \"bio_10.1101_2025.03.06.641947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Partial glial rescue not mechanistically explained\", \"Mammalian cell-type-specific requirement not tested\", \"Alcohol interaction is preprint-stage\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PNPO's metabolic (PLP-generating) and non-canonical (protein-oxidizing, oxygen-sensing, lysosome-regulating) activities are integrated within a single enzyme remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of PNPO bound to non-canonical substrates such as DVL3\", \"Unclear whether signaling functions depend on PLP output or are catalytically independent\", \"Mammalian validation of expanded roles pending\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 7, 11]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [5, 7]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 7]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [8, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DVL3\", \"LAMP2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}